Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)

NCT05503082 is registered in ClinicalTrials.gov with Chicago Headache Center & Research Institute as lead sponsor.

NCT NCT05503082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)
Lead sponsor
Chicago Headache Center & Research Institute
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 6, 2022
Completion date
November 30, 2024
Enrollment
164 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

headache, migraine